{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-295039","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.895550+00:00","generated_at":"2026-06-07T12:51:21.975297+00:00","sec_items":["2.05","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Reneo's mavodelpar fails Phase 3 STRIDE study; cuts workforce 70%","bullets":["Pivotal STRIDE trial of mavodelpar in primary mitochondrial myopathies missed primary endpoint (12MWT at week 24) and key secondary.","Company suspends all mavodelpar development including STRIDE AHEAD; workforce reduced ~70%.","Estimated Q4 2023 charges of ~$2.5M for severance and termination-related costs.","Company has >$100M in cash, cash equivalents, and short-term investments to fund operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-295039","json":"https://secwatch.observer/filing/0001193125-23-295039.json","markdown":"https://secwatch.observer/filing/0001193125-23-295039.md","text":"https://secwatch.observer/filing/0001193125-23-295039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000119312523295039/0001193125-23-295039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000119312523295039/d553352d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:51:21.975297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d9af8f4f356f276e715aec9af72d6e4966e4633","claim":"OnKure Therapeutics, Inc. announced a restructuring with charges of approximately $2.5 million.","evidence_excerpt":"the Company estimates that it will incur charges of approximately $2.5 million associated with cash severance payments and other employee termination-related costs in the fourth quarter of 2023.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312523295039/0001193125-23-295039-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $2.5 million"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}